Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials.
Pamela FerreiraJoão Pedro Ferrari-SouzaCécile TissotBruna BellaverDouglas Teixeira LeffaFiroza LussierGuilherme PovalaJoseph TherriaultAndréa L BenedetNicholas James AshtonAnn D CohenOscar L LopezDana TudorascuWilliam E KlunkJean-Paul SoucySerge GauthierVictor VillemagneHenrik ZetterbergHenrik ZetterbergPedro Rosa-NetoEduardo R ZimmerJonathan M SchottTharick Pascoalnull nullPublished in: Neurology (2023)
Plasma p-tau181/NfL can potentially be used to monitor large-scale population interventions in CU individuals. The enrollment of CU with intermediate Aβ levels constitutes the alternative with the largest effect size and most cost-effective for trials testing drug effect on changes in plasma p-tau181 and NfL.